<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZIAGENÂ - abacavir sulfateÂ tablet, film coatedÂ </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>These highlights do not include all the information needed to use ZIAGEN safely and effectively. See full prescribing information for ZIAGEN.ZIAGEN (abacavir sulfate) Tablets, for oral useZIAGEN (abacavir sulfate) Oral SolutionInitial U.S. Approval: 1998</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1>Boxed Warning section</h1>
<p class="First"></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>: Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been associated with ZIAGEN<span class="Sup">Â®</span> (</span><span class="Bold">abacavir</span><span class="Bold"> sulfate).</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to </span><span class="Bold">abacavir</span><span class="Bold"> is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups: (1) <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, (2) <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, (3) gastrointestinal (including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), (4) constitutional (including generalized <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or achiness), and (5) respiratory (including </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></span><span class="Bold">, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, or </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span></span><span class="Bold">). Discontinue ZIAGEN as soon as a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected.</span></p>
<p><span class="Bold">Patients who carry the HLA-B*5701 allele are at high risk for experiencing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to </span><span class="Bold">abacavir</span><span class="Bold">. Prior to initiating therapy with </span><span class="Bold">abacavir</span><span class="Bold">, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Screening is also recommended prior to </span><span class="Bold">reinitiation</span><span class="Bold"> of </span><span class="Bold">abacavir</span><span class="Bold"> in patients of unknown HLA-B*5701 status who have previously tolerated </span><span class="Bold">abacavir</span><span class="Bold">. HLA-B*5701-negative patients may develop a suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to </span><span class="Bold">abacavir</span><span class="Bold">; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</span></p>
<p><span class="Bold">Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible.</span></p>
<p><span class="Bold">Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to </span><span class="Bold">abacavir</span><span class="Bold">, NEVER restart ZIAGEN or any other </span><span class="Bold">abacavir</span><span class="Bold">-containing product because more severe symptoms can occur within hours and may include life-threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<p><span class="Bold">Reintroduction of ZIAGEN or any other </span><span class="Bold">abacavir</span><span class="Bold">-containing product, even in patients who have no identified history or unrecognized symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to </span><span class="Bold">abacavir</span><span class="Bold"> therapy, can result in serious or fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. Such reactions can occur within hours <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span></span><span class="Bold">: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span></span><span class="Bold"> with </span><span class="Bold">steatosis</span><span class="Bold">, including fatal cases, have been reported with the use of nucleoside analogues alone or in </span><span class="Bold">combination,</span><span class="Bold"> including ZIAGEN and other </span><span class="Bold">antiretrovirals</span><span class="Bold"><span class="Italics">[see Warnings and Precautions (5.2)]</span>.</span></p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>ZIAGEN Tablets and Oral Solution, in combination with other antiretroviral agents, are indicated for the treatment of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Additional important information on the use of ZIAGEN for treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:</p>
<p>ZIAGEN is one of multiple products containing abacavir. Before starting ZIAGEN, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir <span class="Italics">[see Warnings and Precautions (5.1), Adverse Reactions (6)]</span>.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<ul>
<li>A Medication Guide and Warning Card that provide information about recognition of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> should be dispensed with each new prescription and refill. </li>
<li>ZIAGEN may be taken with or without food.</li>
</ul>
<p>
Â 
</p>
<p></p>
<p>The recommended oral dose of ZIAGEN for adults is 600Â mg daily, administered as either 300Â mg twice daily or 600Â mg once daily, in combination with other antiretroviral agents.</p>
<p>
Â 
</p>
<p></p>
<p>The recommended oral dose of ZIAGEN Oral Solution in HIV-1-infected pediatric patients aged 3Â months and older is 8Â mg/kg twice daily (up to a maximum of 300Â mg twice daily) in combination with other antiretroviral agents.</p>
<p>ZIAGEN is also available as a scored tablet for HIV-1-infected pediatric patients weighing greater than or equal to 14Â kg for whom a solid dosage form is appropriate. Before prescribing ZIAGEN Tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow ZIAGEN Tablets, the oral solution formulation should be prescribed. The recommended oral dosage of ZIAGEN Tablets for HIV-1-infected pediatric patients is presented in TableÂ 1.</p>
<a name="_Refid_818bccd3-8f6e-420d-b860-ddd0e2e72"></a><table>
<caption><span>Table 1. Dosing Recommendations for ZIAGEN Tablets in Pediatric Patients</span></caption>
<col span="1" width="12%">
<col span="1" width="19%">
<col span="1" width="19%">
<col span="1" width="13%">
<tbody class="Headless">
<tr class="First">
<td>
<p class="First">Weight</p>
<p>(kg)</p>
</td>
<td><p class="First">Dosage Regimen Using Scored Tablet</p></td>
<td>
<p class="First">Total </p>
<p>Daily Dose</p>
</td>
</tr>
<tr>
<td><p class="First">AM Dose</p></td>
<td><p class="First">PM Dose</p></td>
</tr>
<tr>
<td><p class="First">14 to 21</p></td>
<td><p class="First">Â½ tablet (150Â mg)</p></td>
<td><p class="First">Â½ tablet (150Â mg)</p></td>
<td><p class="First">300Â mg</p></td>
</tr>
<tr>
<td><p class="First">&gt;21 to &lt;30</p></td>
<td><p class="First">Â½ tablet (150Â mg)</p></td>
<td><p class="First">1 tablet (300Â mg)</p></td>
<td><p class="First">450Â mg</p></td>
</tr>
<tr class="Last">
<td><p class="First">â‰¥30</p></td>
<td><p class="First">1 tablet (300Â mg)</p></td>
<td><p class="First">1 tablet (300Â mg)</p></td>
<td><p class="First">600Â mg</p></td>
</tr>
</tbody>
</table>
<p>
Â 
</p>
<p></p>
<p>The recommended dose of ZIAGEN in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 5 to 6) is 200Â mg twice daily. To enable dose reduction, ZIAGEN Oral Solution (10Â mL twice daily) should be used for the treatment of these patients. The safety, efficacy, and pharmacokinetic properties of abacavir have not been established in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; therefore, ZIAGEN is contraindicated in these patients.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>DOSAGE FORMS &amp; STRENGTHS</h1>
<p class="First"></p>
<p>ZIAGEN Tablets contain 300 mg of abacavir as abacavir sulfate. The tablets are yellow, biconvex, scored, capsule-shaped, film-coated, and imprinted with â€œGX 623â€? on both sides.</p>
<p>ZIAGEN Oral Solution contains 20Â mg/mL of abacavir as abacavir sulfate. The solution is a clear to opalescent, yellowish, strawberry-banana-flavored liquid.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>ZIAGEN is contraindicated in patients with: </p>
<ul>
<li>previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir or any other component of the products. NEVER restart ZIAGEN or any other abacavir-containing product following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, regardless of HLA-B*5701 status <span class="Italics">[see Warnings and Precautions (5.1), Adverse Reactions (6)]</span>.</li>
<li>moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Dosage and Administration (2.3)]</span>.</li>
</ul>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been associated with ZIAGEN and other abacavir-containing products. Read full prescribing information section 5.1 before prescribing ZIAGEN. (5.1)</li>
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis have been reported with the use of nucleoside analogues. (5.2)</li>
<li><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> (5.3) and redistribution/accumulation of body fat have been reported in patients treated with combination antiretroviral therapy. (5.4)</li>
</ul>
<p>
Â 
</p>
<p></p>
<p>Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been associated with ZIAGEN and other abacavir-containing products. Patients who carry the HLA-B*5701 allele are at high risk for experiencing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.</p>
<p>HLA-B*5701-negative patients may develop a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible.</p>
<p>Important information on signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, as well as clinical management, is presented below.</p>
<p><span class="Underline">Signs and Symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups.</p>
<p>Group 1: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p>
<p>Group 2: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p>
<p>Group 3: Gastrointestinal (including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>)</p>
<p>Group 4: Constitutional (including generalized <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or achiness)</p>
<p>Group 5: Respiratory (including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>).</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir following the presentation of a single sign or symptom has been reported infrequently.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir was reported in approximately 8% of 2,670Â subjects (nÂ =Â 206) in 9Â clinical trials (range: 2% to 9%) with enrollment from November 1999 to February 2002. Data on time to onset and symptoms of suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> were collected on a detailed data collection module. The frequencies of symptoms are shown in Figure 1. Symptoms usually appeared within the first 6Â weeks of treatment with abacavir, although the reaction may occur at any time during therapy. Median time to onset was 9Â days; 89% appeared within the first 6Â weeks; 95% of subjects reported symptoms from 2 or more of theÂ 5 groups listed above.</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ced433cf-2acf-47ae-9b74-69992c3bc8e0&amp;name=MM1.jpg"></p>
<p>Figure 1. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>-Related Symptoms Reported With â‰¥10% Frequency in Clinical Trials (nÂ =Â 206 Subjects) </p>
<p>Other less common signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> include <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, myolysis, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, abnormal chest x-ray findings (predominantly infiltrates, which can be localized), and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">adult respiratory distress syndrome</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have occurred in association with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. In one trial, 4Â subjects (11%) receiving ZIAGEN 600Â mg once daily experienced <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> compared with 0 subjects receiving ZIAGEN 300Â mg twice daily.</p>
<p>Physical findings associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir in some patients include <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, mucous membrane lesions (<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulcerations</span>), and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. The <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> usually appears maculopapular or urticarial, but may be variable in appearance. There have been reports of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have occurred without <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p>Laboratory abnormalities associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir in some patients include elevated liver function tests, elevated creatine phosphokinase, elevated creatinine, and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>.</p>
<p><span class="Underline">Clinical Management of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> Discontinue ZIAGEN as soon as a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected. To minimize the risk of a life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, permanently discontinue ZIAGEN if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible (e.g., acute onset respiratory diseases such as <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, or <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>; <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>; or reactions to other medications).</p>
<p>Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, NEVER restart ZIAGEN or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>When therapy with ZIAGEN has been discontinued for reasons other than symptoms of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, and if reinitiation of ZIAGEN or any other abacavir-containing product is under consideration, carefully evaluate the reason for discontinuation of ZIAGEN to ensure that the patient did not have symptoms of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, DO NOT reintroduce ZIAGEN or any other abacavir-containing product. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</p>
<p>If symptoms consistent with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> are not identified, reintroduction can be undertaken with continued monitoring for symptoms of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Make patients aware that a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> can occur with reintroduction of ZIAGEN or any other abacavir-containing product and that reintroduction of ZIAGEN or any other abacavir-containing product needs to be undertaken only if medical care can be readily accessed by the patient or others.</p>
<p>Risk Factor<span class="Italics">: HLA-B*5701 Allele:</span> Trials have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir.</p>
<p>CNA106030 (PREDICT-1), a randomized, double-blind trial, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> in abacavir-naive HIV-1-infected adults (nÂ =Â 1,650). In this trial, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> from 7.8% (66/847) to 3.4% (27/803). Based on this trial, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele.</p>
<p>Screening for carriage of the HLA -B*5701 allele is recommended prior to initiating treatment with abacavir. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.</p>
<p>Skin patch testing is used as a research tool and should not be used to aid in the clinical diagnosis of abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p>In any patient treated with abacavir, the clinical diagnosis of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> must remain the basis of clinical decision-making. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</p>
<p>
Â 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including abacavir and other antiretrovirals. A majority of these cases have been in women. <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> and prolonged nucleoside exposure may be risk factors. Particular caution should be exercised when administering ZIAGEN to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with ZIAGEN should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
<p>
Â 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including ZIAGEN. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium </span><span class="Italics">avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis </span><span class="Italics">jirovecii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.</p>
<p><span>Â <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Gravesâ€™ disease, </span><span><span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span></span><span>, and </span><span>Guillain-BarrÃ©</span><span> syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many months after initiation of treatment.</span></p>
<p>
Â 
</p>
<p></p>
<p>Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and â€œcushingoid appearanceâ€? have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
<p>
Â 
</p>
<p></p>
<p>In a published prospective, observational, epidemiological trial designed to investigate the rate of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in patients on combination antiretroviral therapy, the use of abacavir within the previous 6 months was correlated with an increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI).<span class="Sup">1</span> In a sponsor-conducted pooled analysis of clinical trials, no excess risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> was observed in abacavir-treated subjects as compared with control subjects. In totality, the available data from the observational cohort and from clinical trials are inconclusive.</p>
<p>As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, smoking).</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul>
<li>Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. In one trial, once-daily dosing of abacavir was associated with more severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.2)]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</li>
<li>Fat redistribution <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> <span class="Italics">[see Warnings and Precautions (5.5)]</span>.</li>
</ul>
<p>
Â 
</p>
<p></p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Underline">Adults:</span><span class="Italics">Therapy-Naive Adults:</span> Treatment-emergent clinical adverse reactions (rated by the investigator as moderate or severe) with a greater than or equal to 5% frequency during therapy with ZIAGEN 300Â mg twice daily, lamivudine 150Â mg twice daily, and efavirenz 600Â mg daily compared with zidovudine 300Â mg twice daily, lamivudine 150Â mg twice daily, and efavirenz 600Â mg daily from CNA30024 are listed in TableÂ 2.</p>
<a name="_Refid_181528c6-6783-4afd-8e2e-6056e3c68"></a><table>
<caption><span>Table 2. Treatment-Emergent (All Causality) Adverse Reactions of at Least Moderate Intensity (Grades 2-4, â‰¥5%Â Frequency) in Therapy-Naive Adults (CNA30024<span class="Sup">a</span>) Through 48Â Weeks of Treatment</span></caption>
<col span="1" width="35%">
<col span="1" width="39%">
<col span="1" width="41%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Adverse Reaction</p></td>
<td>
<p class="First">ZIAGEN plus Lamivudine plus Efavirenz</p>
<p>(nÂ =Â 324)</p>
</td>
<td>
<p class="First">Zidovudine plus Lamivudine plus Efavirenz</p>
<p>(nÂ =Â 325)</p>
</td>
</tr>
<tr>
<td><p class="First">Dreams/<span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span></p></td>
<td><p class="First">10%</p></td>
<td><p class="First">10%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">Drug hypersensitivity</span></p></td>
<td><p class="First">9%</p></td>
<td><p class="First">&lt;1%<span class="Sup">b</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span></p></td>
<td><p class="First">7%</p></td>
<td><p class="First">11%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td><p class="First">7%</p></td>
<td><p class="First">11%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>/<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p></td>
<td><p class="First">7%</p></td>
<td><p class="First">10%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td><p class="First">7%</p></td>
<td><p class="First">6%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span></p></td>
<td><p class="First">6%</p></td>
<td><p class="First">12%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>/<br>gastrointestinal signs and symptoms</p></td>
<td><p class="First">6%</p></td>
<td><p class="First">8%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive disorders</span></p></td>
<td><p class="First">6%</p></td>
<td><p class="First">6%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td><p class="First">6%</p></td>
<td><p class="First">6%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></p></td>
<td><p class="First">6%</p></td>
<td><p class="First">5%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></p></td>
<td><p class="First">4%</p></td>
<td><p class="First">5%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td><p class="First">2%</p></td>
<td><p class="First">9%</p></td>
</tr>
<tr><td>
<span class="Sup">a</span> This trial used double-blind ascertainment of suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. During the blinded portion of the trial, suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir was reported by investigators in 9% of 324Â subjects in the abacavir group and 3% of 325Â subjects in the zidovudine group.</td></tr>
<tr class="Last"><td>
<span class="Sup">b</span> Ten (3%) cases of suspected <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> were reclassified as not being due to abacavir following unblinding.</td></tr>
</tbody>
</table>
<p>Treatment-emergent clinical adverse reactions (rated by the investigator as moderate or severe) with a greater than or equal to 5% frequency during therapy with ZIAGEN 300Â mg twice daily, lamivudine 150Â mg twice daily, and zidovudine 300Â mg twice daily compared with indinavir 800Â mg 3 times daily, lamivudine 150Â mg twice daily, and zidovudine 300Â mg twice daily from CNA3005 are listed in TableÂ 3.</p>
<a name="_Refid_51e586a9-eaea-4168-874b-2ddd2791d"></a><table>
<caption><span>Table 3. Treatment-Emergent (All Causality) Adverse Reactions of at Least Moderate Intensity (Grades 2-4, â‰¥5% Frequency) in Therapy-Naive Adults (CNA3005) Through 48Â Weeks of Treatment</span></caption>
<col span="1" width="27%">
<col span="1" width="38%">
<col span="1" width="38%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Adverse Reaction</p></td>
<td>
<p class="First">ZIAGEN plus Lamivudine/Zidovudine</p>
<p>(nÂ =Â 262)</p>
</td>
<td>
<p class="First">Indinavir plus Lamivudine/Zidovudine</p>
<p>(nÂ =Â 264)</p>
</td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td><p class="First">19%</p></td>
<td><p class="First">17%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td><p class="First">13%</p></td>
<td><p class="First">9%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></p></td>
<td><p class="First">12%</p></td>
<td><p class="First">12%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></td>
<td><p class="First">10%</p></td>
<td><p class="First">10%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reaction</span></p></td>
<td><p class="First">8%</p></td>
<td><p class="First">2%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td><p class="First">7%</p></td>
<td><p class="First">5%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and/or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></p></td>
<td><p class="First">6%</p></td>
<td><p class="First">3%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive disorders</span></p></td>
<td><p class="First">6%</p></td>
<td><p class="First">4%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></p></td>
<td><p class="First">5%</p></td>
<td><p class="First">7%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span></p></td>
<td><p class="First">5%</p></td>
<td><p class="First">4%</p></td>
</tr>
<tr>
<td><p class="First">Ear/nose/<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span></p></td>
<td><p class="First">5%</p></td>
<td><p class="First">4%</p></td>
</tr>
<tr>
<td><p class="First">Viral <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infections</span></p></td>
<td><p class="First">5%</p></td>
<td><p class="First">5%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td><p class="First">5%</p></td>
<td><p class="First">3%</p></td>
</tr>
<tr>
<td><p class="First">Renal signs/symptoms</p></td>
<td><p class="First">&lt;1%</p></td>
<td><p class="First">5%</p></td>
</tr>
<tr class="Last">
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (non-site-specific)</p></td>
<td><p class="First">&lt;1%</p></td>
<td><p class="First">5%</p></td>
</tr>
</tbody>
</table>
<p>Five subjects receiving ZIAGEN in CNA3005 experienced worsening of pre-existing <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> compared with none in the indinavir arm. The background rates of pre-existing <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> were similar in the 2Â treatment arms.</p>
<p><span class="Italics">ZIAGEN Once Daily Versus ZIAGEN Twice Daily (CNA30021):</span> Treatment-emergent clinical adverse reactions (rated by the investigator as at least moderate) with a greater than or equal to 5% frequency during therapy with ZIAGEN 600Â mg once daily or ZIAGEN 300Â mg twice daily, both in combination with lamivudine 300Â mg once daily and efavirenz 600Â mg once daily from CNA30021, were similar. For <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, subjects receiving ZIAGEN once daily showed a rate of 9% in comparison with a rate of 7% for subjects receiving ZIAGEN twice daily. However, subjects receiving ZIAGEN 600Â mg once daily, experienced a significantly higher incidence of severe <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> reactions and severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> compared with subjects who received ZIAGEN 300Â mg twice daily. Five percent (5%) of subjects receiving ZIAGEN 600Â mg once daily had severe <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> reactions compared with 2% of subjects receiving ZIAGEN 300Â mg twice daily. Two percent (2%) of subjects receiving ZIAGEN 600Â mg once daily had severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> while none of the subjects receiving ZIAGEN 300Â mg twice daily had this event.</p>
<p><span class="Italics">Laboratory Abnormalities:</span> Laboratory abnormalities (Grades 3-4) in therapy-naive adults during therapy with ZIAGEN 300Â mg twice daily, lamivudine 150Â mg twice daily, and efavirenz 600Â mg daily compared with zidovudine 300Â mg twice daily, lamivudine 150Â mg twice daily, and efavirenz 600Â mg daily from CNA30024 are listed in TableÂ 4.</p>
<a name="_Refid_368a3fbf-c3ab-45f4-a3a7-2b09f1b17"></a><table>
<caption><span>Table 4. Laboratory Abnormalities (Grades 3-4) in Therapy-Naive Adults (CNA30024) Through 48 Weeks of Treatment</span></caption>
<col span="1" width="43%">
<col span="1" width="27%">
<col span="1" width="27%">
<tbody class="Headless">
<tr class="First">
<td>
<p class="First">Grade 3/4 </p>
<p>Laboratory Abnormalities</p>
</td>
<td>
<p class="First">ZIAGEN plus</p>
<p>Lamivudine plus Efavirenz</p>
<p>(nÂ =Â 324)</p>
</td>
<td>
<p class="First">Zidovudine plus</p>
<p>Lamivudine plus Efavirenz<br>(nÂ =Â 325)</p>
</td>
</tr>
<tr>
<td><p class="First">Elevated CPK (&gt;4 X ULN)</p></td>
<td><p class="First">8%</p></td>
<td><p class="First">8%</p></td>
</tr>
<tr>
<td><p class="First">Elevated ALT (&gt;5 X ULN)</p></td>
<td><p class="First">6%</p></td>
<td><p class="First">6%</p></td>
</tr>
<tr>
<td><p class="First">Elevated AST (&gt;5 X ULN)</p></td>
<td><p class="First">6%</p></td>
<td><p class="First">5%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (&gt;750Â mg/dL)</p></td>
<td><p class="First">6%</p></td>
<td><p class="First">5%</p></td>
</tr>
<tr>
<td><p class="First">Hyperamylasemia (&gt;2 X ULN)</p></td>
<td><p class="First">4%</p></td>
<td><p class="First">5%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (ANC &lt;750/mm<span class="Sup">3</span>)</p></td>
<td><p class="First">2%</p></td>
<td><p class="First">4%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb â‰¤6.9Â gm/dL)</p></td>
<td><p class="First">&lt;1%</p></td>
<td><p class="First">2%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> (Platelets &lt;50,000/mm<span class="Sup">3</span>)</p></td>
<td><p class="First">1%</p></td>
<td><p class="First">&lt;1%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> (WBC â‰¤1,500/mm<span class="Sup">3</span>)</p></td>
<td><p class="First">&lt;1%</p></td>
<td><p class="First">2%</p></td>
</tr>
<tr><td>ULNÂ =Â Upper limit of normal.</td></tr>
<tr class="Last"><td>nÂ =Â Number of subjects assessed.</td></tr>
</tbody>
</table>
<p>Laboratory abnormalities in CNA3005 are listed in Table 5.</p>
<a name="_Refid_66d090b5-30c7-446a-885b-1d8796fa6"></a><table>
<caption><span>Table 5. Treatment-Emergent Laboratory Abnormalities (Grades 3-4) in CNA3005 </span></caption>
<col span="1" width="36%">
<col span="1" width="25%">
<col span="1" width="38%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Grade 3/4 Laboratory Abnormalities</p></td>
<td><p class="First">Number of Subjects by Treatment Group</p></td>
</tr>
<tr>
<td>
<p class="First">ZIAGEN plus</p>
<p>Lamivudine/Zidovudine</p>
<p>(nÂ =Â 262)</p>
</td>
<td>
<p class="First">Indinavir plus Lamivudine/Zidovudine</p>
<p>(nÂ =Â 264)</p>
</td>
</tr>
<tr>
<td><p class="First">Elevated CPK (&gt;4 x ULN)</p></td>
<td><p class="First">18 (7%)</p></td>
<td><p class="First">18 (7%)</p></td>
</tr>
<tr>
<td><p class="First">ALT (&gt;5.0 x ULN)</p></td>
<td><p class="First">16 (6%)</p></td>
<td><p class="First">16 (6%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (&lt;750/mm<span class="Sup">3</span>)</p></td>
<td><p class="First">13 (5%)</p></td>
<td><p class="First">13 (5%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (&gt;750Â mg/dL)</p></td>
<td><p class="First">5 (2%)</p></td>
<td><p class="First">3 (1%)</p></td>
</tr>
<tr>
<td><p class="First">Hyperamylasemia (&gt;2.0 x ULN)</p></td>
<td><p class="First">5 (2%)</p></td>
<td><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> (&gt;13.9Â mmol/L)</p></td>
<td><p class="First">2 (&lt;1%)</p></td>
<td><p class="First">2 (&lt;1%)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb â‰¤6.9Â g/dL)</p></td>
<td><p class="First">0 (0%)</p></td>
<td><p class="First">3 (1%)</p></td>
</tr>
<tr><td>ULNÂ =Â Upper limit of normal.</td></tr>
<tr class="Last"><td>nÂ =Â Number of subjects assessed.</td></tr>
</tbody>
</table>
<p>The frequencies of treatment-emergent laboratory abnormalities were comparable between treatment groups in CNA30021.</p>
<p><span class="Underline">Pediatric Trials:</span><span class="Italics">Therapy-Experienced Pediatric Subjects:</span> Treatment-emergent clinical adverse reactions (rated by the investigator as moderate or severe) with a greater than or equal to 5% frequency during therapy with ZIAGEN 8Â mg/kg twice daily, lamivudine 4Â mg/kg twice daily, and zidovudine 180Â mg/m<span class="Sup">2</span> twice daily compared with lamivudine 4Â mg/kg twice daily and zidovudine 180Â mg/m<span class="Sup">2</span> twice daily from CNA3006 are listed in TableÂ 6.</p>
<a name="_Refid_6e35becc-a421-4ccb-9368-32d7156e9"></a><table>
<caption><span>Table 6. Treatment-Emergent (All Causality) Adverse Reactions of at Least Moderate Intensity (Grades 2-4, â‰¥5% Frequency) in Therapy-Experienced Pediatric Subjects (CNA3006) Through 16Â Weeks of Treatment</span></caption>
<col span="1" width="26%">
<col span="1" width="43%">
<col span="1" width="29%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Adverse Reaction</p></td>
<td>
<p class="First">ZIAGEN plus Lamivudine plus Zidovudine</p>
<p>(nÂ =Â 102)</p>
</td>
<td>
<p class="First">Lamivudine plus Zidovudine</p>
<p>(nÂ =Â 103)</p>
</td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and/or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></p></td>
<td><p class="First">9%</p></td>
<td><p class="First">7%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></td>
<td><p class="First">9%</p></td>
<td><p class="First">2%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span></p></td>
<td><p class="First">7%</p></td>
<td><p class="First">1%</p></td>
</tr>
<tr>
<td><p class="First">Ear/nose/<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span></p></td>
<td><p class="First">5%</p></td>
<td><p class="First">1%</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></p></td>
<td><p class="First">4%</p></td>
<td><p class="First">5%</p></td>
</tr>
<tr class="Last">
<td><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td><p class="First">1%</p></td>
<td><p class="First">5%</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Laboratory Abnormalities:</span> In CNA3006, laboratory abnormalities (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, liver function test abnormalities, and CPK elevations) were observed with similar frequencies as in a trial of therapy-naive adults (CNA30024). Mild elevations of blood glucose were more frequent in pediatric subjects receiving ZIAGEN (CNA3006) as compared with adult subjects (CNA30024).</p>
<p><span class="Underline">Other Adverse Events:</span> In addition to adverse reactions and laboratory abnormalities reported in Tables 2, 3, 4, 5, and 6, other adverse reactions observed in the expanded access program were <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and increased GGT.</p>
<p>
Â 
</p>
<p></p>
<p>In addition to adverse reactions reported from clinical trials, the following reactions have been identified during postmarketing use of ZIAGEN. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to ZIAGEN.</p>
<p><span class="Underline">Body as a Whole:</span> Redistribution/accumulation of body fat.</p>
<p><span class="Underline">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>.</p>
<p><span class="Underline">Hepatic:</span> <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>.</p>
<p><span class="Underline">Skin:</span> Suspected <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS) and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN) have been reported in patients receiving abacavir primarily in combination with medications known to be associated with SJS and TEN, respectively. Because of the overlap of clinical signs and symptoms between <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir and SJS and TEN, and the possibility of multiple drug sensitivities in some patients, abacavir should be discontinued and not restarted in such cases.</p>
<p>There have also been reports of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> with abacavir use.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First"></p>
<p><span class="Bold">7.1 Ethanol </span></p>
<p>Abacavir has no effect on the pharmacokinetic properties of ethanol. Ethanol decreases the elimination of abacavir causing an increase in overall exposure <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
<p><span class="Bold">7.2 Methadone </span></p>
<p>The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. In a trial of 11Â HIV-1-infected subjects receiving methadone-maintenance therapy with 600Â mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased <span class="Italics">[see Clinical Pharmacology (12.3)]</span>. This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<p>Pregnancy Category C. Studies in pregnant rats showed that abacavir is transferred to the fetus through the placenta. <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">Fetal malformations</span> (increased incidences of fetal <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">anasarca</span> and skeletal malformations) and developmental toxicity (depressed fetal body weight and reduced crown-rump length) were observed in rats at a dose which produced 35Â times the human exposure based on AUC. Embryonic and fetal toxicities (increased resorptions, decreased fetal body weights) and toxicities to the offspring (increased incidence of <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span> and lower body weights) occurred at half of the above-mentioned dose in separate fertility studies conducted in rats. In the rabbit, no developmental toxicity and no increases in <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> occurred at doses that produced 8.5Â times the human exposure at the recommended dose based on AUC.</p>
<p>There are no adequate and well-controlled studies in pregnant women. ZIAGEN should be used during pregnancy only if the potential benefits outweigh the risk.</p>
<p><span class="Underline">Antiretroviral Pregnancy Registry:</span> To monitor maternal-fetal outcomes of pregnant women exposed to ZIAGEN, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
<p>
Â 
</p>
<p></p>
<p>The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Although it is not known if abacavir is excreted in human milk, abacavir is secreted into the milk of lactating rats. Because of both the potential for HIV-1 transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed if they are receiving ZIAGEN.</p>
<p>
Â 
</p>
<p></p>
<p>The safety and effectiveness of ZIAGEN have been established in pediatric patients 3Â months to 13Â years of age. Use of ZIAGEN in these age-groups is supported by pharmacokinetic trials and evidence from adequate and well-controlled trials of ZIAGEN in adults and pediatric patients <span class="Italics">[see Dosage and Administration (2.2), Clinical Pharmacology (12.3), Clinical Studies (14.2)]</span>.</p>
<p>
Â 
</p>
<p></p>
<p>Clinical studies of ZIAGEN did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>There is no known antidote for ZIAGEN. It is not known whether abacavir can be removed by peritoneal dialysis or hemodialysis.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>ZIAGEN is the brand name for abacavir sulfate, a synthetic carbocyclic nucleoside analogue with inhibitory activity against HIV-1. The chemical name of abacavir sulfate is <span class="Italics">(</span>1<span class="Italics">S</span><span class="Italics">,cis</span><span class="Italics">)-</span>4-[2-amino-6-(cyclopropylamino)-9<span class="Italics">H</span>-purin-9-yl]-2-cyclopentene-1-methanol sulfate (salt) (2:1). Abacavir sulfate is the enantiomer with <span class="Italics">1S</span>, <span class="Italics">4R</span> absolute configuration on the cyclopentene ring. It has a molecular formula of (C<span class="Sub">14</span>H<span class="Sub">18</span>N<span class="Sub">6</span>O)<span class="Sub">2</span>â€¢H<span class="Sub">2</span>SO<span class="Sub">4</span> and a molecular weight of 670.76 daltons. It has the following structural formula:</p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ced433cf-2acf-47ae-9b74-69992c3bc8e0&amp;name=MM2.jpg"></p>
<p>Abacavir sulfate is a white to off-white solid with a solubility of approximately 77Â mg/mL in distilled water at 25Â°C. It has an octanol/water (pH 7.1 to 7.3) partition coefficient (log <span class="Italics">P</span>) of approximately 1.20 at 25Â°C.</p>
<p>ZIAGEN Tablets are for oral administration. Each tablet contains abacavir sulfate equivalent to 300Â mg of abacavir as active ingredient and the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The tablets are coated with a film that is made of hypromellose, polysorbate 80, synthetic yellow iron oxide, titanium dioxide, and triacetin.</p>
<p>ZIAGEN Oral Solution is for oral administration. Each milliliter (1Â mL) of ZIAGEN Oral Solution contains abacavir sulfate equivalent to 20Â mg of abacavir (i.e., 20Â mg/mL) as active ingredient and the following inactive ingredients: artificial strawberry and banana flavors, citric acid (anhydrous), methylparaben and propylparaben (added as preservatives), propylene glycol, saccharin sodium, sodium citrate (dihydrate), sorbitol solution, and water.</p>
<p>In vivo, abacavir sulfate dissociates to its free base, abacavir. All dosages for ZIAGEN are expressed in terms of abacavir.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>Abacavir is an antiviral agent <span class="Italics">[See Clinical Pharmacology (12.4)]</span>.</p>
<p>
Â 
</p>
<p></p>
<p><span class="Underline">Pharmacokinetics in Adults:</span> The pharmacokinetic properties of abacavir have been studied in asymptomatic, HIV-1-infected adult subjects after administration of a single intravenous (IV) dose of 150Â mg and after single and multiple oral doses. The pharmacokinetic properties of abacavir were independent of dose over the range of 300 to 1,200Â mg/day.</p>
<p><span class="Italics">Absorption and Bioavailability:</span> Abacavir was rapidly and extensively absorbed after oral administration. The geometric mean absolute bioavailability of the tablet was 83%. After oral administration of 300Â mg twice daily in 20Â subjects, the steady-state peak serum abacavir concentration (C<span class="Sub">max</span>) was 3.0Â Â±Â 0.89Â mcg/mL (meanÂ Â±Â SD) and AUC<span class="Sub">(0-12Â hr)</span> was 6.02Â Â±Â 1.73Â mcgâ€¢hr/mL. After oral administration of a single dose of 600Â mg of abacavir in 20Â subjects, C<span class="Sub">max</span> was 4.26Â Â±Â 1.19Â mcg/mL (meanÂ Â±Â SD) and AUC<span class="Sub">âˆž</span> was 11.95Â Â±Â 2.51Â mcgâ€¢hr/mL.</p>
<p><span class="Italics">Distribution:</span> The apparent volume of distribution after IV administration of abacavir was 0.86Â Â±Â 0.15Â L/kg, suggesting that abacavir distributes into extravascular space. In 3 subjects, the CSF AUC<span class="Sub">(</span><span class="Sub">0-6Â hr)</span> to plasma abacavir AUC<span class="Sub">(0-6Â hr)</span> ratio ranged from 27% to 33%.</p>
<p>Binding of abacavir to human plasma proteins is approximately 50%. Binding of abacavir to plasma proteins was independent of concentration. Total blood and plasma drug-related radioactivity concentrations are identical, demonstrating that abacavir readily distributes into erythrocytes.</p>
<p><span class="Italics">Metabolism:</span> In humans, abacavir is not significantly metabolized by cytochrome P450 enzymes. The primary routes of elimination of abacavir are metabolism by alcohol dehydrogenase (to form the 5â€²-carboxylic acid) and glucuronyl transferase (to form the 5â€²-glucuronide). The metabolites do not have antiviral activity. In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.</p>
<p><span class="Italics">Elimination:</span> Elimination of abacavir was quantified in a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance trial following administration of a 600-mg dose of <span class="Sup">14</span>C-abacavir: 99% of the radioactivity was recovered, 1.2% was excreted in the urine as abacavir, 30% as the 5â€²-carboxylic acid metabolite, 36% as the 5â€²-glucuronide metabolite, and 15% as unidentified minor metabolites in the urine. Fecal elimination accounted for 16% of the dose.</p>
<p>In single-dose trials, the observed elimination half-life (t<span class="Sub">1/2</span>) was 1.54Â Â±Â 0.63Â hours. After intravenous administration, total clearance was 0.80Â Â±Â 0.24 L/hr/kg (meanÂ Â±Â SD).</p>
<p><span class="Underline">Effects of Food on Oral Absorption:</span> Bioavailability of abacavir tablets was assessed in the fasting and fed states. There was no significant difference in systemic exposure (AUC<span class="Sub">âˆž</span>) in the fed and fasting states; therefore, ZIAGEN Tablets may be administered with or without food. Systemic exposure to abacavir was comparable after administration of ZIAGEN Oral Solution and ZIAGEN Tablets. Therefore, these products may be used interchangeably.</p>
<p><span class="Underline">Special Populations:</span><span class="Italics"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> The pharmacokinetic properties of ZIAGEN have not been determined in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Renal excretion of unchanged abacavir is a minor route of elimination in humans. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> The pharmacokinetics of abacavir have been studied in subjects with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 5 to 6). Results showed that there was a mean increase of 89% in the abacavir AUC and an increase of 58% in the half-life of abacavir after a single dose of 600Â mg of abacavir. The AUCs of the metabolites were not modified by mild liver disease; however, the rates of formation and elimination of the metabolites were decreased. A dose of 200Â mg (provided by 10Â mL of ZIAGEN Oral Solution) administered twice daily is recommended for patients with mild liver disease. The safety, efficacy, and pharmacokinetics of abacavir have not been studied in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; therefore, ZIAGEN is contraindicated in these patients.</p>
<p><span class="Italics">Pediatric Patients:</span> The pharmacokinetics of abacavir have been studied after either single or repeat doses of ZIAGEN in 68Â pediatric subjects. Following multiple-dose administration of ZIAGEN 8Â mg/kg twice daily, steady-state AUC<span class="Sub">(</span><span class="Sub">0-12Â hr)</span> and C<span class="Sub">max</span> were 9.8Â Â±Â 4.56Â mcgâ€¢hr/mL and 3.71Â Â±Â 1.36Â mcg/mL (meanÂ Â±Â SD), respectively <span class="Italics">[see Use in Specific Populations (8.4)]</span>. In addition, to support dosing of ZIAGEN scored tablet (300Â mg) for pediatric patients 14 kg to greater than 30Â kg, analysis of actual and simulated pharmacokinetic data indicated comparable exposures are expected following administration of 300Â mg scored tablet and the 8Â mg/kg dosing regimen using oral solution.</p>
<p><span class="Italics">Geriatric Patients:</span> The pharmacokinetics of ZIAGEN have not been studied in patients over 65Â years of age.</p>
<p><span class="Italics">Gender:</span> A population pharmacokinetic analysis in HIV-1-infected male (nÂ =Â 304) and female (nÂ =Â 67) subjects showed no gender differences in abacavir AUC normalized for lean body weight.</p>
<p><span class="Italics">Race:</span> There are no significant differences between blacks and Caucasians in abacavir pharmacokinetics.</p>
<p><span class="Underline">Drug Interactions:</span> In human liver microsomes, abacavir did not inhibit cytochrome P450 isoforms (2C9, 2D6, 3A4). Based on these data, it is unlikely that clinically significant drug interactions will occur between abacavir and drugs metabolized through these pathways. </p>
<p><span class="Italics">Lamivudine</span><span class="Italics"> and/or </span><span class="Italics">Zidovudine</span><span class="Italics">:</span> Due to the common metabolic pathways of abacavir and zidovudine via glucuronyl transferase, 15Â HIV-1-infected subjects were enrolled in a crossover trial evaluating single doses of abacavir (600Â mg), lamivudine (150Â mg), and zidovudine (300Â mg) alone or in combination. Analysis showed no clinically relevant changes in the pharmacokinetics of abacavir with the addition of lamivudine or zidovudine or the combination of lamivudine and zidovudine. Lamivudine exposure (AUC decreased 15%) and zidovudine exposure (AUC increased 10%) did not show clinically relevant changes with concurrent abacavir.</p>
<p><span class="Italics">Ethanol:</span> Due to the common metabolic pathways of abacavir and ethanol via alcohol dehydrogenase, the <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between abacavir and ethanol was studied in 24Â HIV-1-infected male subjects. Each subject received the following treatments on separate occasions: a single 600-mg dose of abacavir, 0.7Â g/kg ethanol (equivalent to 5Â alcoholic drinks), and abacavir 600Â mg plus 0.7Â g/kg ethanol. Coadministration of ethanol and abacavir resulted in a 41% increase in abacavir AUC<span class="Sub">âˆž</span> and a 26% increase in abacavir t<span class="Sub">1/2</span>. In males, abacavir had no effect on the pharmacokinetic properties of ethanol, so no clinically significant interaction is expected in men. This interaction has not been studied in females.</p>
<p><span class="Italics">Methadone:</span> In a trial of 11Â HIV-1-infected subjects receiving methadone-maintenance therapy (40Â mg and 90Â mg daily), with 600Â mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI: 6% to 42%). This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients. The addition of methadone had no clinically significant effect on the pharmacokinetic properties of abacavir.</p>
<p>
Â 
</p>
<p></p>
<p>Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted by cellular enzymes to the active metabolite, carbovir triphosphate (CBV-TP), an analogue of deoxyguanosine-5â€²-triphosphate (dGTP). CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. The lack of a 3â€²-OH group in the incorporated nucleotide analogue prevents the formation of the 5â€² to 3â€² phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. CBV-TP is a weak inhibitor of cellular DNA polymerases Î±, Î², and Î³.</p>
<p><span class="Underline">Antiviral Activity:</span> The antiviral activity of abacavir against HIV-1 was evaluated against a T-cell tropic laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> HIV-1<span class="Sub">IIIB</span> in lymphoblastic cell lines, a monocyte/macrophage tropic laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> HIV<span class="Italics">-</span>1<span class="Sub">BaL</span> in primary monocytes/macrophages, and clinical isolates in peripheral blood mononuclear cells. The concentration of drug necessary to effect viral replication by 50Â percent (EC<span class="Sub">50</span>) ranged from 3.7 to 5.8Â Î¼M (1Â Î¼MÂ =Â 0.28Â mcg/mL) and 0.07 to 1.0Â Î¼M against HIV-1<span class="Sub">IIIB</span> and HIV-1<span class="Sub">BaL</span>, respectively, and was 0.26Â Â±Â 0.18Â Î¼M against 8Â clinical isolates. The EC<span class="Sub">50</span> values of abacavir against different HIV-1 clades (A-G) ranged from 0.0015 to 1.05Â Î¼M, and against HIV-2 isolates, from 0.024 to 0.49Â Î¼M. Abacavir had synergistic activity in cell culture in combination with the nucleoside reverse transcriptase inhibitor (NRTI) zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, and the protease inhibitor (PI) amprenavir; and additive activity in combination with the NRTIs didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zalcitabine. Ribavirin (50Â Î¼M) had no effect on the antiâ€“HIV-1 activity of abacavir in cell culture.</p>
<p><span class="Underline">Resistance:</span> HIV-1 isolates with reduced susceptibility to abacavir have been selected in cell culture and were also obtained from subjects treated with abacavir. Genotypic analysis of isolates selected in cell culture and recovered from abacavir-treated subjects demonstrated that amino acid substitutions K65R, L74V, Y115F, and M184V/I in RT contributed to abacavir resistance. In a trial of therapy-naive adults receiving ZIAGEN 600Â mg once daily (nÂ =Â 384) or 300Â mg twice daily (nÂ =Â 386), in a background regimen of lamivudine 300Â mg once daily and efavirenz 600Â mg once daily (CNA30021), the incidence of virologic failure at 48Â weeks was similar between the 2 groups (11% in both arms). Genotypic (nÂ =Â 38) and phenotypic analyses (nÂ =Â 35) of virologic failure isolates from this trial showed that the RT substitutions that emerged during abacavir once-daily and twice-daily therapy were K65R, L74V, Y115F, and M184V/I. The substitution M184V/I was the most commonly observed substitution in virologic failure isolates from subjects receiving abacavir once daily (56%, 10/18) and twice daily (40%, 8/20).</p>
<p>Thirty-nine percent (7/18) of the isolates from subjects who experienced virologic failure in the abacavir once-daily arm had a greater than 2.5-fold decrease in abacavir susceptibility with a median-fold decrease of 1.3 (range: 0.5 to 11) compared with 29% (5/17) of the failure isolates in the twice-daily arm with a median-fold decrease of 0.92 (range: 0.7 to 13).</p>
<p><span class="Underline">Cross-Resistance:</span> Cross-resistance has been observed among NRTIs. Isolates containing abacavir resistance-associated substitutions, namely, K65R, L74V, Y115F, and M184V, exhibited cross-resistance to didanosine, emtricitabine, lamivudine, tenofovir, and zalcitabine in cell culture and in subjects. The K65R substitution can confer resistance to abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zalcitabine; the L74V substitution can confer resistance to abacavir, didanosine, and zalcitabine; and the M184V substitution can confer resistance to abacavir, didanosine, emtricitabine, lamivudine, and zalcitabine. An increasing number of thymidine analogue mutations (TAMs: M41L, D67N, K70R, L210W, T215Y/F, K219E/R/H/Q/N) is associated with a progressive reduction in abacavir susceptibility.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<p><span class="Underline">Carcinogenicity</span>: Abacavir was administered orally at 3Â dosage levels to separate groups of mice and rats in 2-year carcinogenicity studies. Results showed an increase in the incidence of malignant and non-<span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span>. <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">Malignant tumors</span> occurred in the preputial gland of males and the clitoral gland of females of both species, and in the liver of female rats. In addition, non-<span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span> also occurred in the liver and thyroid gland of female rats. These observations were made at systemic exposures in the range of 6 to 32Â times the human exposure at the recommended dose. It is not known how predictive the results of rodent carcinogenicity studies may be for humans.</p>
<p><span class="Underline">Mutagenicity</span>: Abacavir induced chromosomal aberrations both in the presence and absence of metabolic activation in an inÂ vitro cytogenetic study in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Abacavir was mutagenic in the absence of metabolic activation, although it was not mutagenic in the presence of metabolic activation in an L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay. Abacavir was clastogenic in males and not clastogenic in females in an inÂ vivo mouse bone marrow micronucleus assay.</p>
<p>Abacavir was not mutagenic in bacterial mutagenicity assays in the presence and absence of metabolic activation.</p>
<p><span class="Underline">Impairment of Fertility</span>: Abacavir had no adverse effects on the mating performance or fertility of male and female rats at a dose approximately 8Â times the human exposure at the recommended dose based on body surface area comparisons.</p>
<p>
Â 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Myocardial degeneration</span> was found in mice and rats following administration of abacavir for 2 years. The systemic exposures were equivalent to 7 to 24 times the expected systemic exposure in humans. The clinical relevance of this finding has not been determined.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<p><span class="Underline">Therapy-Naive Adults:</span> CNA30024 was a multicenter, double-blind, controlled trial in which 649Â HIV-1-infected, therapy-naive adults were randomized and received either ZIAGEN (300Â mg twice daily), lamivudine (150Â mg twice daily), and efavirenz (600Â mg once daily); or zidovudine (300Â mg twice daily), lamivudine (150Â mg twice daily), and efavirenz (600Â mg once daily). The duration of double-blind treatment was at least 48Â weeks. Trial participants were male (81%), Caucasian (51%), black (21%), and Hispanic (26%). The median age was 35Â years; the median pretreatment CD4+Â cell count was 264Â cells/mm<span class="Sup">3</span>, and median plasma HIV-1 RNA was 4.79Â log<span class="Sub">10</span>Â copies/mL. The outcomes of randomized treatment are provided in Table 7.</p>
<a name="_Refid_1eb57c61-8283-458e-87df-b6365bf8e"></a><table>
<caption><span>Table 7. Outcomes of Randomized Treatment Through Week 48 (CNA30024) </span></caption>
<col span="1" width="36%">
<col span="1" width="39%">
<col span="1" width="41%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Outcome</p></td>
<td>
<p class="First">ZIAGEN plus Lamivudine plus Efavirenz</p>
<p>(n = 324)</p>
</td>
<td>
<p class="First">Zidovudine plus Lamivudine plus Efavirenz</p>
<p>(n = 325)</p>
</td>
</tr>
<tr>
<td><p class="First">Responder<span class="Sup">a</span></p></td>
<td><p class="First">69% (73%)</p></td>
<td><p class="First">69% (71%)</p></td>
</tr>
<tr>
<td><p class="First">Virologic failures<span class="Sup">b</span></p></td>
<td><p class="First">6%</p></td>
<td><p class="First">4%</p></td>
</tr>
<tr>
<td><p class="First">Discontinued due to adverse reactions</p></td>
<td><p class="First">14%</p></td>
<td><p class="First">16%</p></td>
</tr>
<tr>
<td><p class="First">Discontinued due to other reasons<span class="Sup">c</span></p></td>
<td><p class="First">10%</p></td>
<td><p class="First">11%</p></td>
</tr>
<tr><td>
<span class="Sup">a</span> Subjects achieved and maintained confirmed HIV-1 RNA â‰¤50Â copies/mL (&lt;400Â copies/mL) through Week 48 (Roche AMPLICOR Ultrasensitive HIV-1 MONITOR<span class="Sup">Â®</span> standard test 1.0 PCR).</td></tr>
<tr><td>
<span class="Sup">b</span> Includes viral rebound, insufficient viral response according to the investigator, and failure to achieve confirmed â‰¤50Â copies/mL by Week 48.</td></tr>
<tr class="Last"><td>
<span class="Sup">c</span> Includes consent withdrawn, lost to follow up, protocol violations, those with missing data, clinical progression, and other.</td></tr>
</tbody>
</table>
<p>After 48 weeks of therapy, the median CD4+ cell count increases from baseline were 209Â cells/mm<span class="Sup">3</span> in the group receiving ZIAGEN and 155Â cells/mm<span class="Sup">3</span> in the zidovudine group. Through Week 48, 8Â subjects (2%) in the group receiving ZIAGEN (5 CDC classification C events and 3 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>) and 5 subjects (2%) on the zidovudine arm (3 CDC classification C events and 2 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>) experienced clinical disease progression.</p>
<p>CNA3005 was a multicenter, double-blind, controlled trial in which 562Â HIV-1-infected, therapy-naive adults were randomized to receive either ZIAGEN (300Â mg twice daily) plus COMBIVIR<span class="Sup">Â®</span> (lamivudine 150Â mg/zidovudine 300Â mg twice daily), or indinavir (800Â mg 3Â times a day) plus COMBIVIR twice daily. The trial was stratified at randomization by pre-entry plasma HIV-1 RNA 10,000 to 100,000Â copies/mL and plasma HIV-1 RNA greater than 100,000Â copies/mL. Trial participants were male (87%), Caucasian (73%), black (15%), and Hispanic (9%). At baseline the median age was 36Â years; the median baseline CD4+Â cell count was 360Â cells/mm<span class="Sup">3</span>, and median baseline plasma HIV-1 RNA was 4.8Â log<span class="Sub">10</span>Â copies/mL. Proportions of subjects with plasma HIV-1 RNA less than 400Â copies/mL (using Roche AMPLICOR HIV-1 MONITOR Test) through 48Â weeks of treatment are summarized in Table 8.</p>
<a name="_Refid_f425e0f1-5d2a-40bb-ba08-8320123f9"></a><table>
<caption><span>Table 8. Outcomes of Randomized Treatment Through Week 48 (CNA3005)</span></caption>
<col span="1" width="37%">
<col span="1" width="38%">
<col span="1" width="25%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Outcome</p></td>
<td>
<p class="First">ZIAGEN plus Lamivudine/Zidovudine</p>
<p>(nÂ =Â 262)</p>
</td>
<td>
<p class="First">Indinavir plus </p>
<p>Lamivudine/Zidovudine</p>
<p>(nÂ =Â 265)</p>
</td>
</tr>
<tr>
<td><p class="First">Responder<span class="Sup">a</span></p></td>
<td><p class="First">49%</p></td>
<td><p class="First">50%</p></td>
</tr>
<tr>
<td><p class="First">Virologic failure<span class="Sup">b</span></p></td>
<td><p class="First">31%</p></td>
<td><p class="First">28%</p></td>
</tr>
<tr>
<td><p class="First">Discontinued due to adverse reactions</p></td>
<td><p class="First">10%</p></td>
<td><p class="First">12%</p></td>
</tr>
<tr>
<td><p class="First">Discontinued due to other reasons<span class="Sup">c</span></p></td>
<td><p class="First">11%</p></td>
<td><p class="First">10%</p></td>
</tr>
<tr><td>
<span class="Sup">a</span> Subjects achieved and maintained confirmed HIV-1 RNA &lt;400Â copies/mL.</td></tr>
<tr><td>
<span class="Sup">b</span> Includes viral rebound and failure to achieve confirmed &lt;400Â copies/mL by Week 48. </td></tr>
<tr class="Last"><td>
<span class="Sup">c</span> Includes consent withdrawn, lost to follow up, protocol violations, those with missing data, clinical progression, and other.</td></tr>
</tbody>
</table>
<p>Treatment response by plasma HIV-1 RNA strata is shown in Table 9.</p>
<a name="_Refid_24828044-39ca-47e8-b3ee-15ce1879e"></a><table>
<caption><span>Table 9. Proportions of Responders Through Week 48 By Screening Plasma HIV-1 RNA Levels (CNA3005)</span></caption>
<col span="1" width="21%">
<col span="1" width="29%">
<col span="1" width="9%">
<col span="1" width="19%">
<col span="1" width="6%">
<tbody class="Headless">
<tr class="First">
<td>
<p class="First">Screening </p>
<p>HIV-1 RNA</p>
<p>(copies/mL)</p>
</td>
<td>
<p class="First">ZIAGEN plus Lamivudine/Zidovudine</p>
<p>(nÂ =Â 262)</p>
</td>
<td>
<p class="First">Indinavir plus </p>
<p>Lamivudine/Zidovudine</p>
<p>(nÂ =Â 265)</p>
</td>
</tr>
<tr>
<td><p class="First">&lt;400Â copies/mL</p></td>
<td><p class="First">n</p></td>
<td><p class="First">&lt;400Â copies/mL</p></td>
<td><p class="First">n</p></td>
</tr>
<tr>
<td><p class="First">â‰¥10,000 - â‰¤100,000</p></td>
<td><p class="First">50%</p></td>
<td><p class="First">166</p></td>
<td><p class="First">48%</p></td>
<td><p class="First">165</p></td>
</tr>
<tr class="Last">
<td><p class="First">&gt;100,000</p></td>
<td><p class="First">48%</p></td>
<td><p class="First">96</p></td>
<td><p class="First">52%</p></td>
<td><p class="First">100</p></td>
</tr>
</tbody>
</table>
<p>In subjects with baseline viral load greater than 100,000Â copies/mL, percentages of subjects with HIV-1 RNA levels less than 50Â copies/mL were 31% in the group receiving abacavir versus 45% in the group receiving indinavir.</p>
<p>Through WeekÂ 48, an overall mean increase in CD4+ cell count of about 150Â cells/mm<span class="Sup">3</span> was observed in both treatment arms. Through Week 48, 9Â subjects (3.4%) in the group receiving abacavir sulfate (6Â CDC classification C events and 3Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>) and 3Â subjects (1.5%) in the group receiving indinavir (2Â CDC classification C events and 1Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) experienced clinical disease progression. </p>
<p>CNA30021 was an international, multicenter, double-blind, controlled trial in which 770Â HIV-1-infected, therapy-naive adults were randomized and received either abacavir 600Â mg once daily or abacavir 300Â mg twice daily, both in combination with lamivudine 300Â mg once daily and efavirenz 600Â mg once daily. The double-blind treatment duration was at least 48Â weeks. Trial participants had a mean age of 37Â years; were male (81%), Caucasian (54%), black (27%), and American Hispanic (15%). The median baseline CD4+ cell count was 262Â cells/mm<span class="Sup">3</span> (range 21 to 918Â cells/mm<span class="Sup">3</span>) and the median baseline plasma HIV-1 RNA was 4.89Â log<span class="Sub">10Â </span>copies/mL (range: 2.60 to 6.99Â log<span class="Sub">10Â </span>copies/mL).</p>
<p>The outcomes of randomized treatment are provided in Table 10.</p>
<a name="_Refid_2b8c89ef-803f-4ee0-8425-9197c682f"></a><table>
<caption><span>Table 10. Outcomes of Randomized Treatment Through Week 48 (CNA30021)</span></caption>
<col span="1" width="33%">
<col span="1" width="41%">
<col span="1" width="42%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Outcome</p></td>
<td>
<p class="First">ZIAGEN 600 mg q.d. plus EPIVIR plus Efavirenz</p>
<p>(nÂ =Â 384)</p>
</td>
<td>
<p class="First">ZIAGEN 300 mg b.i.d. plus EPIVIR plus Efavirenz</p>
<p>(nÂ =Â 386)</p>
</td>
</tr>
<tr>
<td><p class="First">Responder<span class="Sup">a</span></p></td>
<td><p class="First">64% (71%)</p></td>
<td><p class="First">65% (72%)</p></td>
</tr>
<tr>
<td><p class="First">Virologic failure<span class="Sup">b</span></p></td>
<td><p class="First">11% (5%)</p></td>
<td><p class="First">11% (5%)</p></td>
</tr>
<tr>
<td><p class="First">Discontinued due to adverse reactions</p></td>
<td><p class="First">13%</p></td>
<td><p class="First">11%</p></td>
</tr>
<tr>
<td><p class="First">Discontinued due to other reasons<span class="Sup">c</span></p></td>
<td><p class="First">11%</p></td>
<td><p class="First">13%</p></td>
</tr>
<tr><td>
<span class="Sup">a</span> Subjects achieved and maintained confirmed HIV-1 RNA &lt;50Â copies/mL (&lt;400Â copies/mL) through Week 48 (Roche AMPLICOR Ultrasensitive HIV-1 MONITOR standard test version 1.0).</td></tr>
<tr><td>
<span class="Sup">b</span> Includes viral rebound, failure to achieve confirmed &lt;50Â copies/mL (&lt;400Â copies/mL) by WeekÂ 48, and insufficient viral load response.</td></tr>
<tr class="Last"><td>
<span class="Sup">c</span> Includes consent withdrawn, lost to follow up, protocol violations, clinical progression, and other.</td></tr>
</tbody>
</table>
<p>After 48 weeks of therapy, the median CD4+ cell count increases from baseline were 188 cells/mm<span class="Sup">3</span> in the group receiving abacavir 600 mg once daily and 200 cells/mm<span class="Sup">3</span> in the group receiving abacavir 300 mg twice daily. Through Week 48, 6 subjects (2%) in the group receiving ZIAGEN 600 mg once daily (4Â CDC classification C events and 2 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>) and 10 subjects (3%) in the group receiving ZIAGEN 300 mg twice daily (7Â CDC classification C events and 3Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>) experienced clinical disease progression. None of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were attributed to trial medications. </p>
<p>
Â 
</p>
<p></p>
<p><span class="Underline">Therapy-Experienced Pediatric Subjects:</span> CNA3006 was a randomized, double-blind trial comparing ZIAGEN 8Â mg/kg twice daily plus lamivudine 4Â mg/kg twice daily plus zidovudine 180Â mg/m<span class="Sup">2</span> twice daily versus lamivudine 4Â mg/kg twice daily plus zidovudine 180Â mg/m<span class="Sup">2</span> twice daily. Two hundred and five therapy-experienced pediatric subjects were enrolled: female (56%), Caucasian (17%), black (50%), Hispanic (30%), median age of 5.4Â years, baseline CD4+ cell percent greater than 15% (medianÂ = 27%), and median baseline plasma HIV-1 RNA of 4.6Â log<span class="Sub">10</span>Â copies/mL. Eighty percent and 55% of subjects had prior therapy with zidovudine and lamivudine, respectively, most often in combination. The median duration of prior nucleoside analogue therapy was 2Â years. At 16Â weeks the proportion of subjects responding based on plasma HIV-1 RNA less than or equal to 400Â copies/mL was significantly higher in subjects receiving ZIAGEN plus lamivudine plus zidovudine compared with subjects receiving lamivudine plus zidovudine, 13% versus 2%, respectively. Median plasma HIV-1 RNA changes from baseline were -0.53Â log<span class="Sub">10 </span>copies/mLÂ in the group receiving ZIAGEN plus lamivudine plus zidovudine compared with -0.21Â log<span class="Sub">10</span>Â copies/mL in the group receiving lamivudine plus zidovudine. Median CD4+ cell count increases from baseline were 69Â cells/mm<span class="Sup">3</span> in the group receiving ZIAGEN plus lamivudine plus zidovudine and 9Â cells/mm<span class="Sup">3</span> in the group receiving lamivudine plus zidovudine.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"></p>
<ol><li>Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. <span class="Italics">Lancet</span>. 2008;371 (9622):1417-1426.</li></ol>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>ZIAGEN Tablets, containing abacavir sulfate equivalent to 300Â mg abacavir are yellow, biconvex, scored, capsule-shaped, film-coated, and imprinted with â€œGX 623â€? on both sides. They are packaged as follows:</p>
<p>Bottles of 60 tablets (NDC 49702-221-18).</p>
<p>Unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 60 tablets (NDC 49702-221-44). Each pack contains 6 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards of 10 tablets each.</p>
<p><span class="Bold">Store at controlled room temperature of 20Â° to 25Â°C (68Â° to 77Â°F) (see USP).</span></p>
<p>ZIAGEN Oral Solution is a clear to opalescent, yellowish, strawberry-banana-flavored liquid. Each mL of the solution contains abacavir sulfate equivalent to 20Â mg of abacavir. It is packaged in plastic bottles as follows:</p>
<p>Bottles of 240Â mL (NDC 49702-222-48) with child-resistant closure. This product does not require reconstitution.</p>
<p><span class="Bold">Store at controlled room temperature of 20Â° to 25Â°C (68Â° to 77Â°F) (see USP). DO NOT FREEZE. </span><span class="Bold">May be refrigerated.</span></p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<p class="First"></p>
<p>See FDA-approved patient labeling (Medication Guide)</p>
<p>
Â 
</p>
<p></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span>:</span> Inform patients:</p>
<ul>
<li>that a Medication Guide and Warning Card summarizing the symptoms of the abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> and other product information will be dispensed by the pharmacist with each new prescription and refill of ZIAGEN, and encourage the patient to read the Medication Guide and Warning Card every time to obtain any new information that may be present about ZIAGEN. (The complete text of the Medication Guide is reprinted at the end of this document.)</li>
<li>to carry the Warning Card with them.</li>
<li>how to identify a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> <span class="Italics">[see Medication Guide]</span>.</li>
<li>that if they develop symptoms consistent with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> they should call their doctor right away to determine if they should stop taking ZIAGEN.</li>
<li>that a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> can worsen and lead to hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if ZIAGEN is not immediately discontinued.</li>
<li>that in one trial, more severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> were seen when ZIAGEN was dosed 600Â mg once daily.</li>
<li>to not restart ZIAGEN or any other abacavir-containing product following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> because more severe symptoms can occur within hours and may include life-threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li>that a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is usually reversible if it is detected promptly and ZIAGEN is stopped right away.</li>
<li>that if they have interrupted ZIAGEN for reasons other than symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (for example, those who have an interruption in drug supply), a serious or fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> may occur with reintroduction of abacavir.</li>
<li>to not restart ZIAGEN or any other abacavir-containing product without medical consultation and that restarting abacavir needs to be undertaken only if medical care can be readily accessed by the patient or others.</li>
<li>ZIAGEN should not be coadministered with EPZICOM<span class="Sup">Â®</span> (abacavir sulfate and lamivudine) Tablets or TRIZIVIR<span class="Sup">Â®</span> (abacavir sulfate, lamivudine, and zidovudine) Tablets.</li>
</ul>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/</span><span class="Underline"><span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span></span><span class="Underline">:</span> Inform patients that some HIV medicines, including ZIAGEN, can cause a rare, but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.2)]</span>.</p>
<p><span class="Underline">Redistribution/Accumulation of Body Fat:</span> Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</p>
<p><span class="Underline">Information </span><span class="Underline">About</span><span class="Underline"> HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span> ZIAGEN is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients should remain under the care of a physician when using ZIAGEN. </p>
<p>Patients should be advised to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<ul>
<li><span class="Bold">Do not share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood. </li>
<li>
<span class="Bold">Do not breastfeed.</span> We do not know if ZIAGEN can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.</li>
</ul>
<p>Patients should be informed to take all HIV medications exactly as prescribed. </p>
<p>COMBIVIR, EPIVIR, EPZICOM, TRIZIVIR, and ZIAGEN are registered trademarks of ViiV Healthcare.</p>
<p>Manufactured for:</p>
<p>ViiV Healthcare</p>
<p>Research Triangle Park, NC 27709</p>
<p>by:</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Â©2012, ViiV Healthcare. All rights reserved.</p>
<p>ZGN:6PI</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-17"></a><p></p>
<h1>SPL MEDGUIDE</h1>
<p class="First"></p>
<p><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">ZIAGEN<span class="Sup">Â®</span> (ZY-uh-</span><span class="Bold">jen</span><span class="Bold">)</span></p>
<p>(abacavir sulfate)</p>
<p><span class="Bold">Tablets and Oral Solution</span></p>
<p>Read this Medication Guide before you start taking ZIAGEN and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. Be sure to carry your ZIAGEN Warning Card with you at all times.</p>
<p><span class="Bold">What is the most important information I should know about ZIAGEN?</span></p>
<p><span class="Bold">1.Serious</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>).</span> ZIAGEN contains abacavir (also contained in EPZICOM<span class="Sup">Â®</span> and TRIZIVIR<span class="Sup">Â®</span>). Patients taking ZIAGEN may have a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>) that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your risk of this <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> is much higher if you have a gene variation called HLA-B*5701. Your healthcare provider can determine with a blood test if you have this gene variation.</p>
<p><span class="Bold">If you get a symptom from 2 or more of the following groups while taking ZIAGEN, call your healthcare provider right away to find out if you should stop taking ZIAGEN.</span></p>
<table>
<col span="1" width="11%">
<col span="1" width="61%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td><p class="First"><span class="Bold">Symptom(s)</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Group 1</span></p></td>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Group 2</span></p></td>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Group 3</span></p></td>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, abdominal (stomach area) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Group 4</span></p></td>
<td><p class="First"><span class="Bold">Generally ill feeling, extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, or achiness</span></p></td>
</tr>
<tr class="Last">
<td><p class="First"><span class="Bold">Group 5</span></p></td>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> </span></p></td>
</tr>
</tbody>
</table>
<p>A list of these symptoms is on the Warning Card your pharmacist gives you. <span class="Bold">Carry this Warning Card with you at all times.</span></p>
<p><span class="Bold">If you stop ZIAGEN because of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, never take ZIAGEN (</span><span class="Bold">abacavir</span><span class="Bold"> sulfate) or any other </span><span class="Bold">abacavir</span><span class="Bold">-containing medicine (EPZICOM and TRIZIVIR) again</span>. If you take ZIAGEN or any other abacavir-containing medicine again after you have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="Bold">within hours</span> you may get <span class="Bold">life-threatening symptoms</span> that may include <span class="Bold">very <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> </span>or<span class="Bold"> <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span>If you stop ZIAGEN, for any other reason, even for a few days, and you are not allergic to ZIAGEN, talk with your healthcare provider before taking it again. Taking ZIAGEN again can cause a serious allergic or life-threatening reaction, even if you never had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to it before.</p>
<p><span class="Bold">If your healthcare provider tells you that you can take ZIAGEN again, start taking it when you are around medical help or people who can call a healthcare provider if you need one.</span></p>
<p><span class="Bold">2. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> (buildup of acid in the blood). Some human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) medicines, including ZIAGEN, can cause a rare but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a serious medical emergency that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and must be treated in the hospital. </span></p>
<p><span class="Bold">Call your healthcare provider right away if you get any of the following signs or symptoms of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>: </span></p>
<ul>
<li>you feel very weak or tired</li>
<li>you have unusual (not normal) <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></li>
<li>you have trouble breathing</li>
<li>you have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>you feel <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, especially in your arms and legs</li>
<li>you feel dizzy or light-headed</li>
<li>you have a fast or irregular heartbeat</li>
</ul>
<p><span class="Bold">3. Serious liver problems. Some people who have taken medicines like ZIAGEN have developed serious liver problems called </span><span class="Bold">hepatotoxicity</span><span class="Bold">, with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (</span><span class="Bold"><span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span></span><span class="Bold">) and fat in the liver (</span><span class="Bold">steatosis</span><span class="Bold">). </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span></span><span class="Bold"> with </span><span class="Bold">steatosis</span><span class="Bold"> is a serious medical emergency that can cause </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.Call</span><span class="Bold"> your healthcare provider right away if you get any of the following signs or symptoms of liver problems:</span></p>
<ul>
<li>your skin or the white part of your eyes turns yellow (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
<li>your urine turns dark </li>
<li>your bowel movements (stools) turn light in color</li>
<li>you donâ€™t feel like eating food for several days or longer</li>
<li>you feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>)</li>
<li>you have lower stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p><span class="Bold">You may be more likely to get <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or serious liver problems if you are female, very overweight, or have been taking nucleoside analogue medicines for a long time.</span></p>
<p><span class="Bold">What is ZIAGEN?</span></p>
<p>ZIAGEN is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. ZIAGEN is a medicine called a nucleoside analogue reverse transcriptase inhibitor (NRTI). ZIAGEN is always used with other anti-HIV medicines. When used in combination with these other medicines, ZIAGEN helps lower the amount of HIV in your blood. </p>
<ul>
<li><span class="Bold">ZIAGEN does not cure <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> or AIDS.</span></li>
<li>It is not known if ZIAGEN will help you live longer or have fewer of the medical problems that people get with HIV or AIDS.</li>
<li>It is very important that you see your doctor regularly while you are taking ZIAGEN.</li>
</ul>
<p><span class="Bold">Who should not take ZIAGEN?</span></p>
<p><span class="Bold">Do not take ZIAGEN if you:</span></p>
<ul>
<li>
<span class="Bold">are</span><span class="Bold"> allergic to </span><span class="Bold">abacavir</span><span class="Bold"> or any of the ingredients in ZIAGEN. See the end of this Medication Guide for a complete list of ingredients in ZIAGEN. </span>
</li>
<li>
<span class="Bold">have</span><span class="Bold"> certain liver problems.</span>
</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking ZIAGEN?</span></p>
<p><span class="Bold">Before you take ZIAGEN, </span><span class="Bold">tell your healthcare provider</span><span class="Bold"> if you:</span></p>
<ul>
<li>
<span class="Bold">have</span><span class="Bold"> been tested and know whether or not you have a particular gene variation called HLA-B*5701.</span>
</li>
<li>
<span class="Bold">have</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or have other liver problems.</span>
</li>
<li>
<span class="Bold">have</span><span class="Bold"> heart problems, smoke, or have diseases that increase your risk of heart disease such as high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</span>
</li>
<li>
<span class="Bold">are</span><span class="Bold"> pregnant or plan to become pregnant.</span> It is not known if ZIAGEN will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.<br><span class="Bold">Pregnancy Registry.</span> If you take ZIAGEN while you are pregnant, talk to your healthcare provider about how you can take part in the Pregnancy Registry for ZIAGEN. The purpose of the pregnancy registry is to collect information about the health of you and your baby.</li>
<li>
<span class="Bold">are</span><span class="Bold"> breastfeeding or plan to breastfeed. Do not breastfeed.</span> We do not know if ZIAGEN can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and nonprescription medicines, vitamins, and herbal supplements.</p>
<p><span class="Bold">Especially tell your healthcare provider if you take:</span></p>
<ul>
<li>alcohol</li>
<li>methadone</li>
<li>TRIZIVIR (abacavir sulfate, lamivudine, and zidovudine)</li>
<li>EPZICOM (abacavir sulfate and lamivudine)</li>
</ul>
<p>Ask your healthcare provider if you are not sure if you take one of the medicines listed above.</p>
<p>ZIAGEN may affect the way other medicines work, and other medicines may affect how ZIAGEN works.</p>
<p>Know the medicines you take. Keep a list of your medicines with you to show to your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take ZIAGEN?</span></p>
<ul>
<li><span class="Bold">Take ZIAGEN exactly as your healthcare provider tells you to take it.</span></li>
<li><span class="Bold">ZIAGEN is taken by mouth as a tablet or a strawberry- and banana-flavored liquid.</span></li>
<li>ZIAGEN may be taken with or without food.</li>
<li>Do not skip doses.</li>
<li>Children aged 3Â months and older can also take ZIAGEN. The childâ€™s healthcare provider will decide the right dose and whether the child should take the tablet or liquid, based on the childâ€™s weight. The dose should not be more than the recommended adult dose.</li>
<li>
<span class="Bold">Do not let your ZIAGEN run out.</span><br>If you stop your anti-HIV medicines, even for a short time, the amount of virus in your blood may increase and the virus may become harder to treat. If you take too much ZIAGEN, call your healthcare provider or poison control center or go to the nearest hospital emergency room right away.</li>
</ul>
<p><span class="Bold">What are the possible side effects of ZIAGEN?</span></p>
<ul>
<li><span class="Bold">ZIAGEN can cause serious side effects including <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, and liver problems. See â€œWhat is the most important information I should know about ZIAGEN?â€?</span></li>
<li>
<span class="Bold">Changes in immune system (<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span>).</span> Your immune system may get stronger and begin to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that have been hidden in your body for a long time. Tell your healthcare provider if you start having new or worse symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> after you start taking ZIAGEN.</li>
<li>
<span class="Bold">Changes in body fat (fat redistribution).</span> Changes in body fat (<span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span> or <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>) can happen in some people taking antiretroviral medicines including ZIAGEN.</li>
</ul>
<p>Â These changes may include:</p>
<ul>
<li>more fat in or around your trunk, upper back and neck (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), breast, or chest</li>
<li>loss of fat in your legs, arms, or face</li>
</ul>
<ul><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>).</span> Some HIV medicines including ZIAGEN may increase your risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</li></ul>
<p><span class="Bold">The most common side effects of ZIAGEN in adults include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">bad dreams</span> or <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problems</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
<p><span class="Bold">The most common side effects of ZIAGEN in children include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li>ear, nose, or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span></li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of ZIAGEN. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store ZIAGEN?</span></p>
<ul>
<li>Store ZIAGEN at room temperature, between 68Â°F to 77Â°F (20Â°C to 25Â°C).</li>
<li>Do not freeze ZIAGEN.</li>
<li><span class="Bold">Keep ZIAGEN and all medicines out of the reach of children.</span></li>
</ul>
<p><span class="Bold">General information for safe and effective use of ZIAGEN</span></p>
<p>Avoid doing things that can spread <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> to others.</p>
<ul>
<li><span class="Bold">Do not share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
</ul>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ZIAGEN for a condition for which it was not prescribed. Do not give ZIAGEN to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about ZIAGEN. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for the information that is written for healthcare professionals.</p>
<p>For more information go to <a href="#_Ref">www.ZIAGEN.com</a> or call 1-877-844-8872.</p>
<p><span class="Bold">What are the ingredients in ZIAGEN?</span></p>
<p><span class="Bold">Tablets </span></p>
<p>Active ingredient: abacavir sulfate</p>
<p>Inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate, and afilmâ€‘coating made of hypromellose, polysorbate 80, synthetic yellow iron oxide, titanium dioxide, and triacetin.</p>
<p><span class="Bold">Oral Solution</span></p>
<p>Active ingredient: abacavir sulfate</p>
<p>Inactive ingredients: artificial strawberry and banana flavors, citric acid (anhydrous), methylparaben and propylparaben (added as preservatives), propylene glycol, saccharin sodium, sodium citrate (dihydrate), sorbitol solution, and water.</p>
<p>This Medication Guide has been approved by the US Food and Drug Administration.</p>
<p>EPZICOM and TRIZIVIR are registered trademarks of ViiV Healthcare.</p>
<p>Manufactured for:</p>
<p>ViiV Healthcare</p>
<p>Research Triangle Park, NC 27709</p>
<p>by:</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Â©2012, ViiV Healthcare. All rights reserved.</p>
<p>May 2012</p>
<p>ZGN:5MG</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: ZIAGEN </p>
<p><br></p>
<p>GENERIC: abacavir sulfate</p>
<p><br></p>
<p>DOSAGE: TABLET, FILM COATED</p>
<p><br></p>
<p>ADMINSTRATION: ORAL</p>
<p><br></p>
<p>NDC: 49349-905-02</p>
<p><br></p>
<p>STRENGTH:300 mg</p>
<p><br></p>
<p>COLOR: yellow</p>
<p><br></p>
<p>SHAPE: OVAL</p>
<p><br></p>
<p>SCORE: Two even pieces</p>
<p><br></p>
<p>SIZE: 18 mm</p>
<p><br></p>
<p>IMPRINT: GX 623</p>
<p><br></p>
<p>QTY: 30</p>
<p><br></p>
<p><br></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ced433cf-2acf-47ae-9b74-69992c3bc8e0&amp;name=MM3.jpg"></p>
<p><img alt="MM4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ced433cf-2acf-47ae-9b74-69992c3bc8e0&amp;name=MM4.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZIAGENÂ 		
					</strong><br><span class="contentTableReg">abacavir sulfate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49349-905(NDC:49702-221)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ABACAVIR SULFATE</strong> (ABACAVIR) </td>
<td class="formItem">ABACAVIR</td>
<td class="formItem">300Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (TABLET, FILM COATED) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GX;623</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49349-905-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020977</td>
<td class="formItem">04/08/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b034da3a-ee5d-4edf-b5d7-471efb8fff2a</div>
<div>Set id: ced433cf-2acf-47ae-9b74-69992c3bc8e0</div>
<div>Version: 1</div>
<div>Effective Time: 20130408</div>
</div>
</div>Â <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
